The Impact of Psoriasis and Atopic Dermatitis on Quality of Life: A Literature Research on Biomarkers

Abstract

Psoriasis (PSO) and Atopic dermatitis (AD) are common inflammatory skin diseases that affect people of all ages globally. They negatively impact the quality of life (QoL) of patients in health-related aspects such as physical, psychological and mental functioning. Here, we conducted a review of studies relating to candidate biomarkers and indicators associated with QoL impairment in PSO and AD. Data research was performed using PUBMED and SCOPUS databases from inception to September 2022. Most of the included studies reported genomic or proteomic biomarkers associated with disease activity and QoL outcomes. Sociodemographic, clinical and therapeutic factors have also been implicated in deterioration of life quality in these patients. The inclusion of clinical characteristics, QoL impairment and co-diagnosis should be considered in drug development programs, since processing biomarkers based on an increased number of features in addition to drug class and disease will intensify the value of the biomarker itself, thereby maximizing the future clinical utility as a stratification tool.

Impact of residual skin lesions and previous biologic treatment failure on patient‐reported outcomes in patients with psoriasis receiving biologic treatment

“…Our analysis did not establish a significant association between DLQI scores and age, sex, or comorbidities, in contrast to some previous studies 35–37 . This difference may be attributed to variations in study populations and treatment modalities.…”

“…34 Our analysis did not establish a significant association between DLQI scores and age, sex, or comorbidities, in contrast to some previous studies. [35][36][37] This difference may be attributed to variations in study populations and treatment modalities. Previous studies on patient-reported outcomes in psoriasis often included topical Our study has some limitations that should be acknowledged.…”

Comparative Analysis of Redox Homeostasis Biomarkers in Patients with Psoriasis and Atopic Dermatitis

“…A lot of effort has been made to identify biomarkers that would best reflect the disease onset and progression [10]. However, a reliable marker that would differentiate PsO from AD has rarely been examined [11,12] and has not been established yet.…”

Niosomal Curcumin Suppresses IL17/IL23 Immunopathogenic Axis in Skin Lesions of Psoriatic Patients: A Pilot Randomized Controlled Trial

“…Although the hyperproliferation of keratinocytes is the most remarkable characteristic of PS, the underlying mechanism of the loss of control is not well studied. Environmental factors, genetic background, and immune responses may be involved in the pathogenesis of PS [ 10 ]. Although the immunopathological mechanisms underlying this disease with defective immune responses are not yet fully understood, research has highlighted the significant roles played by immune cells located in the dermis and epidermis, such as dendritic cells (DCs) and T lymphocytes (T cells) [ 11 , 12 ].…”